Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01196104 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler
A Phase 3 study, sponsored by Mannkind Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 39
- Enrollment target
NCT01196104 is a Phase 3 study that was terminated before completion, run by Mannkind Corporation. The registered enrollment target is 39 participants.
The verdict
NCT01196104, a Phase 3 study, was terminated before completion, sponsored by Mannkind Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is an open-label, randomized, forced-titration clinical trial evaluating the efficacy and safety of Technosphere Insulin (TI) Inhalation Powder in combination with insulin glargine versus insulin aspart in combination with insulin glargine in subjects with type 2 diabetes.
Interventions
- DRUG Insulin Glargine
- DRUG Insulin Aspart
- DRUG Technosphere® Insulin Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01196104
The ClinicalTrials.gov registry entry for NCT01196104 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Insulin Glargine is the first listed.
NCT01196104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01196104 about?
NCT01196104 is a clinical study titled "Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler". This is an open-label, randomized, forced-titration clinical trial evaluating the efficacy and safety of Technosphere Insulin (TI) Inhalation Powder in combination with insulin glargine versus insulin aspart in combination with insulin glargine in subjects with type 2 diabetes.
What is the current status of trial NCT01196104?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 39 participants. The study started on 2010-09. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01196104?
The interventions under investigation include: Insulin Glargine (DRUG), Insulin Aspart (DRUG), Technosphere® Insulin Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT01196104?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.